Takeda Pharmaceutical Company Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Julie So-Young Kim
- Full Time Employees
- 47,029
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1-1, Nihonbashi-Honcho 2-chome Tokyo OS Japan 103-8668
- IPO Date
- Jan 5, 2010
- CIK
- 0001395064
- Website
- takeda.com
- Similar Companies
- Business
- Takeda Pharmaceutical Company Limited operates globally, dedicated to the research, development, production, and commercialization of innovative biopharmaceutical treatments. The company focuses its scientific efforts and delivers therapies across several key areas: gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its portfolio includes prominent brands such as Entyvio for inflammatory bowel diseases, Vyvanse for ADHD, and Takhzyro for rare genetic conditions, alongside various other products for oncology and plasma-derived needs. With operations spanning approximately 80 countries and regions worldwide, Takeda maintains a significant presence across Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific. The company actively engages in strategic alliances and licensing agreements to advance its pipeline and expand its market reach. Recent collaborations include a notable $11.4 billion deal with China's Innovent Biologics in October 2025 to accelerate immuno-oncology and antibody-drug conjugate cancer therapies. Additionally, Takeda expanded its partnership with Beacon Biosignals in November 2025 to further narcolepsy diagnosis and neurobiomarker discovery. The company also received FDA approval for Eohilia, an oral treatment for allergic inflammation of the esophagus, in February 2024. Founded in 1781, Takeda is headquartered in Tokyo, Japan, and remains a leading global biopharmaceutical firm driven by a patient-centric approach and commitment to sustainable healthcare solutions. It consistently invests substantially in research and development, with a robust late-stage pipeline aimed at delivering life-transforming medicines.
Takeda's QDENGA becomes first dengue vaccine approved in India
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results